HOME最近の話題次回の研究会研究会の歩み役立ち情報keywords意見交換リンク

2008年12月12日(金)

FDA????LABA????????????????

投稿者: ????????

?12?6??TOPICS??????????FDA??12?10-11??2???????????????????????????????????2??????LABAs?long acting beta-2 adrenergic agonists????????????????????????????????????????????????????????????????????????????????????

?????????????????????????????????LABAs???Serevent???????? Foradil????????Advair???????Symbicort?????????????????????????????????????????

??????LABAs???Serevent?Foradil??????????????????????????????????????Advair?Symbicort??????????????????????????????????????????????????????????????

Brand Name ?? ?? 12?17? 4?11?
Serevent ??????? ????? ???? ????
Foradil ????????? ???? ???? ????
Advair ?????????????? ???? ???? ?????
Symbicort ??????????????? ???? ???? ??????

??????????????????????????LABA???????????????????LABA??????????????????????????????LABA????????????????????????????????????????????????????????????Advair?Symbicort??????????????????????????

????Serevent?Foradil?COPD????????FDA?????????????????????????????????????????????????????????????????

????Advair???????????????????????????????????????????????????????????????????????????????????????LABA???????????????????????????????????????????????????????????????????????????

??????????????????????LABA????????????????????????????LABA??????????????????????????????????????

?????2008.12.06????????2??????????????FDA?

????????????????????????????????
??????????????????????2008.6.20?
???http://www.yakugai.gr.jp/attention/attention.php?id=205

???
FDA Advisers Would End Asthma Indications for Two Long-Acting Beta2 Agonists
???Medpage TODAY 2008.12.11?
?http://www.medpagetoday.com/AllergyImmunology/Asthma/12126
Two Asthma Meds May Be Too Risky, FDA Panel Says
???HealthDay 2008.12.11?
?http://www.healthday.com/Article.asp?AID=622182
F.D.A. Panel Votes to Ban Asthma Drugs
??(New York Times 2008.12.11)
?http://www.nytimes.com/2008/12/12/health/policy/12fda.html

Topに戻る  

コメント (0)

この記事にはまだコメントがついていません。

現在、この記事へのコメントは頂いておりません。

Copyright(C) Ryomo Apotheker Network, All rights reserved, since 2004